Document:

Severance and Release Agreement

 Exhibit 10.1 
 SEVERANCE AND RELEASE AGREEMENT 
 This SEVERANCE AND RELEASE
AGREEMENT (this “Agreement”) is being entered into by and between Auxilium Pharmaceuticals, Inc. (“Auxilium” or the “Company”), and Armando Anido (hereinafter “Mr. Anido”).

 Background 
 Mr. Anido and Auxilium are parties to that certain Amended and Restated Employment Agreement having an effective date of December 23, 2010 (the “Employment Agreement”).

 Mr. Anido and the Company have mutually agreed that Mr. Anido’s employment with Auxilium will end on
December 7, 2011 (the “Termination Date”), and Mr. Anido will resign from the Board of Directors of the Company (the “Board”), including any committees of the Board or committees of any subsidiaries of the
Company, effective on the Termination Date. 
 Each of Auxilium and Mr. Anido desire to enter into this Agreement to fully
resolve all questions of expenses, compensation, entitlement to benefits, and any and all other claims, whether known or unknown, which Mr. Anido may have relating to his employment and his termination of that employment with the Company.

 Terms and Conditions 
 NOW, THEREFORE, in consideration of the mutual promises contained in this Agreement and intending to be legally bound and for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto hereby agree as follows: 
 1. Effective as of the Termination Date, Mr. Anido will
cease to serve as Chief Executive Officer and President of the Company. The Company acknowledges that Mr. Anido’s resignation was not voluntary and, therefore, a termination without Cause (as defined in the Employment Agreement), and, as
such, Mr. Anido shall be entitled to those benefits and payments as are provided for in Section 2.1 of the Employment Agreement on the terms and subject to the conditions set forth therein and Mr. Anido’s continued compliance
with the terms hereof. The Company further acknowledges that as Mr. Anido has agreed to tender his resignation as an officer of the Company and each of its subsidiaries effective as of the Termination Date, Mr. Anido shall be entitled to
receive 30-days’ Base Salary (as defined in the Employment Agreement) in lieu of notice as provided for in Section 2.1(a) of the Employment Agreement, which amount equals $48,100. Such $48,100, as reduced by any applicable tax withholdings
and normal deductions, will be paid to Mr. Anido on December 23, 2011 as part of the Company’s regular pay cycle on such date. Mr. Anido shall resign from the Board, including any committees of the Board or committees of any
subsidiaries of Auxilium effective on the Termination Date. 

 2. Subject in all respects to this Agreement, including, without limitation the release of
claims set forth in paragraph 4 hereof and Mr. Anido’s compliance with the terms hereof, becoming effective and enforceable in accordance with paragraph 10 hereof, Auxilium shall provide payments described in (a) and (b) below,
less appropriate withholdings taxes and deductions. In addition, regardless of whether this Agreement becomes effective and enforceable in accordance with paragraph 10 hereof, Mr. Anido shall be entitled to the other benefits described in
(c) and, with respect to the first 90 days following the Termination Date, (d) below. 
 (a) Payment
in the gross amount of $1,906,800. This amount will be paid in 24 equal monthly installments commencing within 60 days following the Termination Date. 
 (b) Provided Executive timely elects COBRA continuation coverage, reimbursement of the monthly COBRA medical insurance cost (less any required employee payments calculated as if Executive had continued to
be an employee) during the 18 month period following the Termination Date for Mr. Anido, and (if applicable) dependents. Following the 18-month period, if Mr. Anido secures an individual policy for health coverage (for himself and any
dependents), Auxilium will reimburse Mr. Anido for the monthly cost of such coverage for 6 months, provided that the amount does not exceed the monthly COBRA continuation coverage costs. All other benefits associated with his employment will be
discontinued on the Termination Date, subject to any conversion rights that Mr. Anido may have. The COBRA health care continuation period shall run concurrently with the foregoing period. 

(c) Mr. Anido will also be compensated for his earned, but unused, vacation time through the Termination Date, which
amount is $37,740. Such $37,740, as reduced by any applicable tax withholdings, will be paid to Mr. Anido on December 23, 2011 as part of the Company’s regular pay cycle on such date. 

(d) All outstanding stock options and restricted stock units that would have become vested during the 24-month period
following the Termination Date will become fully vested as of the Termination Date. In accordance with the terms of the applicable grant agreements pursuant to which they were granted and the Company’s 2004 Equity Compensation Plan, including
the determination by the Compensation Committee of the Board to extend the post termination exercise period of such stock options, Mr. Anido has until September 7, 2012 to exercise all outstanding options that have vested as of the
Termination Date; provided however, that if Mr. Anido breaches any of his obligations under this Agreement or Sections 4, 5, 6, and 7 of the Employment Agreement, any vested and unexercised options shall terminate immediately and automatically
be deemed forfeited as of the date of such breach. Subject to Section 2.1(b)(iii) of the Employment Agreement, outstanding options and restricted stock units that have not 

  
 2 

 
vested as of the Termination Date will be forfeited. For the avoidance of doubt, with respect to the Restricted Stock Unit Grant Agreement by and between Auxilium and Mr. Anido dated
February 17, 2011, if the Committee (as defined therein) determines that all or any portion of the Performance Goal (as defined therein) is achieved, then Mr. Anido shall be immediately vested in the right to receive 66% of the shares of
Company Stock (as defined therein) earned upon achievement of such Performance Goal. Information regarding the vested options will be provided under separate cover. 
 3. Mr. Anido agrees to submit final travel and expense reports to Human Resources by December 28, 2011 and to cooperate with the immediate return of all Company property, as applicable; provided
that Mr. Anido may retain his Company purchase i-Phone, i-Pad and laptop computer so long as Mr. Anido cooperates with the Company to remove all Company-related information from such devices. 

4. MR. ANIDO, FOR HIMSELF AND HIS RESPECTIVE ADMINISTRATORS, EXECUTORS, AGENTS, BENEFICIARIES AND ASSIGNS, AGREES TO WAIVE, RELEASE AND
FOREVER DISCHARGE AUXILIUM PHARMACEUTICALS, INC. (AS DEFINED BELOW) OF AND FROM ANY AND ALL CLAIMS (AS DEFINED BELOW). Mr. Anido further agrees that should any other person, organization or entity file a lawsuit or
arbitration to assert any such Claim, he will not seek any personal relief in such an action. This General Release of Claims provision (this “Release”) covers all Claims arising from the beginning of time up to and including the
date of this Agreement. 
 Exclusions: Notwithstanding any other provision of this Release, the following are not
barred by the Release: (a) Claims relating to the validity of this Agreement; (b) Claims by either party to enforce this Agreement; (c) Claims which legally may not be waived; (d) Claims for any vested benefits under any of
Auxilium’s employee benefit plans, and (e) Claims for indemnification pursuant to Auxilium’s by-laws or other corporate governance documents or policies or pursuant to any directors and officers or other insurance policies covering
Mr. Anido. In addition, this Release does not bar Mr. Anido’s right to file an administrative charge with the Equal Employment Opportunity Commission (“EEOC”) and/or to participate in an investigation by the EEOC,
although the Release does bar Mr. Anido’s right to recover any personal relief if he or any person, organization, or entity asserts a charge on his behalf, including in a subsequent lawsuit or arbitration. 

The following provisions further explain this Release: 

(a) Definition of “Claims”. Except as stated above, “Claims” includes without limitation all
actions or demands of any kind that Mr. Anido now has or may have or claim to have in the future. More specifically, Claims include rights, causes of action, damages, penalties, losses, attorneys’ fees, costs, expenses, obligations,
agreements, judgments and all other liabilities of any kind or description whatsoever, 

  
 3 

 
either in law or in equity, whether known or unknown, suspected or unsuspected. 
 The nature of Claims covered by this Release includes without limitation all actions or demands in any way based on Mr. Anido’s employment with the Company, the terms and conditions of such
employment or Mr. Anido’s separation from employment. More specifically, all of the following are among the types of Claims which, to the extent permitted by law, are waived and barred by this Release: 

 

	 	•	 	 Contract Claims (whether express or implied); 

  

	 	•	 	 Tort Claims, such as for tortious interference, defamation or emotional distress; 

 

	 	•	 	 Claims under federal, state and municipal laws, regulations, ordinance or court decisions of any kind; 

 

	 	•	 	 Claims of discrimination, harassment or retaliation, whether based on race, color, religion, gender, sex, age, sexual orientation, handicap and/or
disability, national origin, whistleblowing or any other legally protected class; 

  

	 	•	 	 Claims under the AGE DISCRIMINATION IN EMPLOYMENT ACT, Title VII of the Civil Rights Act of 1964, as amended, the Americans with Disabilities Act and
similar state and local laws; 

  

	 	•	 	 Claims under the Employee Retirement Income Security Act, the Occupational Safety and Health Act and similar state and local laws;

  

	 	•	 	 Claims for wrongful discharge; and 

  

	 	•	 	 Claims for attorney’s fees, litigation expenses and/or costs. 

The foregoing list is intended to be illustrative and not exhaustive. 

(b) Definition of “Auxilium Pharmaceuticals, Inc.” “Auxilium Pharmaceuticals, Inc.” includes,
without limitation, Auxilium Pharmaceuticals, Inc. and its respective past, present and future parents, affiliates, subsidiaries, divisions, predecessors, successors, assigns, employee benefit plans and trusts. It also includes all past, present and
future managers, directors, officers, partners, agents, employees, attorneys, representatives, consultants, associates, fiduciaries, plan sponsors, administrators and trustees of each of the foregoing. 

5. Mr. Anido expressly acknowledges that: 

  
 4 

 (a) He remains bound by Sections 4, 5, 6, and 7 of the Employment
Agreement, which remain in full force and effect, and whose remaining in full force and effect is reasonably and properly required for the protection of the Company’s business; and, in keeping with the foregoing, Mr. Anido explicitly and
specifically acknowledges that among his obligations thereunder, he may not directly or indirectly solicit or recruit any employee of Auxilium to work for a third party other than Auxilium (excluding newspaper or similar print or electronic
solicitations of general circulation); 
 (b) The provisions of Section 8 of the Employment Agreement
remain in full force and effect; 
 (c) Auxilium’s obligation to provide him with the benefits set forth in
paragraph 2 above are contingent upon his ongoing compliance with Sections 4, 5, 6, and 7 of the Employment Agreement and his obligations under this Agreement; 
 (d) He will not disparage the personal or professional reputation of Auxilium, its directors, officers, or employees. Auxilium will direct its officers and directors not to disparage the personal or
professional reputation of Mr. Anido. Nothing in this section is intended to prohibit or restrict Mr. Anido or Auxilium, its officers and directors from making any disclosure of information required by law or participating in an otherwise
legally protected activity, such as an investigation or proceeding by a federal regulatory or law enforcement agency or legislative body; 
 (e) He shall cooperate with Auxilium with respect to any legal issue regarding any matter of which he had knowledge during his employment with Auxilium. His cooperation includes appearance at depositions,
assistance in responding to discovery demands, preparation for trials, and appearance at trial. Auxilium will reimburse Mr. Anido for all reasonable expenses incurred by him in providing such assistance; 

(f) Mr. Anido shall provide, upon the reasonable request of the Chief Executive Officer and President of Auxilium
(“CEO”), advice and support solely and directly to the CEO on a variety of matters related to Auxilium’s business (the “Services”). Mr. Anido shall perform the Services for a reasonable period of time per month during
the six-month period following the Termination Date, unless the parties agree otherwise, and Mr. Anido shall perform the Services telephonically or electronically. In requesting that Mr. Anido perform Services, Auxilium will reasonably
accommodate Mr. Anido’s schedule with regard to other work for which he may be responsible. Under no circumstances shall Mr. Anido, in the course of performing the Services or otherwise, be provided with any material non-public
information within the meaning of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. No breach of this Section 5(f) shall be deemed to have occurred unless Auxilium provides Mr. Anido with written notice describing with

  
 5 

 
particularity the manner in which it alleges this Section 5(f) has been breached, Auxilium provides Mr. Anido with 15 days after his receipt of such written notice to cure any such
alleged breach, and, after the expiration of such 15 day period, the Company determines that such breach has not been cured; and 
 (g) After the Termination Date, Auxilium will not have any obligation to provide Mr. Anido at any time in the future with any payments, benefits or considerations other than those recited in
subsections (a) through (d) of paragraph 2 above and any vested benefits to which Mr. Anido may be entitled under the terms of Auxilium’s benefit plans. 
 6. By entering into this Agreement, the Company does not admit and expressly denies that it has violated any contract, rule or law, including but not limited to, any federal, state and local statute or
law relating to employment or employment discrimination. 
 7. Mr. Anido understands and acknowledges that by signing this
Agreement and accepting the terms contained herein he is receiving benefits that he would not otherwise be entitled to. Mr. Anido acknowledges that he is receiving this payment in exchange for entering into this Agreement and complying with all
the provisions of this Agreement. 
 8. Mr. Anido acknowledges that he has been advised in writing to consult with an
attorney before signing this Agreement. 
 9. Mr. Anido acknowledges that he has been provided with a period of at least 21
calendar days to consider the terms of this offer from the date this Agreement first was presented to him on December 7, 2011. No changes to this offer, whether material or immaterial, will restart the running of the foregoing consideration
period. 
 Mr. Anido shall notify Auxilium of his acceptance of this Agreement by delivering a signed copy to the Company,
addressed to Jennifer Armstrong. Mr. Anido understands that he may take the entire 21 day period to consider this Agreement. Mr. Anido may not return this Agreement prior to the Termination Date. If Mr. Anido does not notify Auxilium
of his acceptance of this Agreement by delivering a signed copy to the Company, addressed to Jennifer Armstrong, Mr. Anido shall have no further right to receive the payments recited in subsections (a) and (b) of paragraph 2 above.

 By signing and returning this Agreement, Mr. Anido acknowledges that the consideration period afforded him a reasonable
period of time to consider fully each and every term of this Agreement, including the General Release of Claims set forth in paragraph 4 above, and that he has given the terms full and complete consideration. 

10. If Mr. Anido notifies Auxilium of his acceptance of this Agreement by delivering a signed copy to the Company addressed to
Jennifer Armstrong as described above, Mr. Anido may revoke the Agreement for a period of seven days. The Agreement shall not become 

  
 6 

 
effective or enforceable until the seven-day revocation period has ended. For revocation to be effective, it must be delivered to Jennifer Armstrong, Auxilium Pharmaceuticals, Inc., 40 Valley
Stream Parkway, Malvern, PA 19355. 
 11. Mr. Anido, intending to be legally bound, certifies and warrants that he has
read carefully this Agreement and has executed it voluntarily and with full knowledge and understanding of its significance, meaning and binding effect. Mr. Anido further declares he is competent to understand the content and effect of this
Agreement and that his decision to enter into this Agreement has not been influenced in any way by fraud, duress, coercion, mistake or misleading information. 
 12. This Agreement will take effect on the first business day following the expiration of the revocation period specified in paragraph 10 hereof, provided that Mr. Anido chooses not to revoke it.

 13. Mr. Anido may not assign his rights or obligations under this Agreement or the Employment Agreement. Auxilium may
assign this Agreement to a successor or assignee in connection with a merger, consolidation or sale or transfer of assets. 

14. If any provision of this Agreement is or shall be declared invalid or unenforceable by a court of competent jurisdiction, the
remaining provisions shall not be affected thereby and shall remain in full force and effect. 
 15. The construction,
interpretation and performance of this Agreement shall be governed by the laws of the Commonwealth of Pennsylvania without regard to any choice of law or conflict of law, choice of forum or provision, rule or principle (whether of the Commonwealth
of Pennsylvania or any other jurisdiction) that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 
 16. This Agreement supersedes any and all prior agreements or understandings between Mr. Anido and Auxilium, except those provisions of the Employment Agreement identified above. Mr. Anido
represents and acknowledges that in executing this Agreement he has not relied upon any representation or statement not set forth herein made by the Auxilium Pharmaceuticals, Inc. (as defined in paragraph 4(b) hereof) with regard to the subject
matter of this Agreement. Any modification of this Agreement must be made in writing and signed by all parties. 

[Signature Page Follows] 

  
 7 

 As evidenced by their signatures below, the parties intend to be legally bound by this
Agreement. 
  

			
	 /s/ Armando Anido

	Armando Anido
		
	DATE:	 	 December 23, 2011

	
	AUXILIUM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ James E. Fickenscher

	Name:	 	 James E. Fickenscher

	Title:	 	 Chief Financial Officer

		
	Date:	 	 December 23, 2011

  
 8Form of Stock Option Agreement

 Exhibit 10.5 
 ORACLE CORPORATION 
 STOCK OPTION AGREEMENT 

2000 LONG-TERM EQUITY INCENTIVE PLAN 
 U.S. NON-QUALIFIED STOCK OPTION 
 FOR U.S. EXECUTIVE VICE PRESIDENTS AND
SECTION 16 OFFICERS 
  

	1.	 Grant.    Oracle Corporation (the “Company”) has granted to the optionee (“Optionee”) named above a
U.S. non-qualified option (the “Option”) to purchase the total number of shares of Common Stock set forth above (the “Shares”) at the exercise price per share set forth above (the “Exercise Price”). This Option is
subject to the terms set forth below in this stock option agreement (the “Agreement”) and in the Company’s 2000 Long-Term Equity Incentive Plan as amended to date (the “Plan”). In the event of a conflict between the terms of
the Plan and the terms of this Agreement, the terms of the Plan shall govern. All capitalized terms not defined herein shall have the meanings ascribed to them in the Plan. 

 

	2.	 Restrictions on Exercise.    Subject to the terms of the Plan and this Agreement, the Option may be exercised in
increments on or after each vesting date specified above, provided that in no event may the Option be exercised after the last date to exercise specified above (the “Expiration Date”). In addition, this Option may not be exercised as to
fewer than 100 Shares unless it is exercised as to all Shares as to which this Option is then exercisable. 

 The Optionee agrees to comply with the Insider Trading restrictions applicable to the Company’s officers for one fiscal quarter following the Optionee’s termination of his/her employment
relationship with the Company or any Parent, Subsidiary or Affiliate of the Company, regardless of the reason for such termination. Under these restrictions, the Optionee may be prohibited from trading in the Company’s securities during the
last month of the fiscal quarter and until two full trading days following the Company’s earnings announcement for that fiscal quarter. Notwithstanding the foregoing, this Option is subject to the time limitations on exercise set forth in
Section 6(i) of the Plan and Section 3 below (the “Remaining Option Exercise Period”); provided that if any “No Trading” period under Oracle’s Insider Trading Policy occurs during the Remaining Option Exercise
Period and the Optionee is prohibited from trading during such period, the Remaining Option Exercise Period shall be extended by the number of days equivalent to any such periods such that the total amount of time the Optionee shall have to exercise
the vested portion of this Option shall be equal to the original Remaining Option Exercise Period (except that, if the Expiration Date of the Option occurs during this additional extension period, such Option shall still expire on the Expiration
Date and the additional extension period shall not be extended beyond the Expiration Date). 
  

	3.	 Termination of Option. 

  

	 	a)	 This Option shall cease vesting upon termination of Optionee’s employment relationship with Optionee’s employer (excluding a transfer to
the Company or one of its Subsidiaries or Affiliates) and shall not be extended by any notice or equivalent period mandated under local law (e.g., a period of “garden leave” or similar period pursuant to local law) or as may be
required by the terms of an employment agreement. An Optionee’s employment relationship shall be considered to have terminated, and the Optionee to have ceased to be employed by the Company or its Parent, Subsidiary or Affiliate, on the
earliest of: 

  
 1 

	 	(1)	 the date on which Optionee’s employer (the “Employer”) delivers to the Optionee notice terminating the employment relationship
(regardless of whether the notice or termination is lawful or unlawful or is in breach of any contract of employment) unless the Optionee is transferring employment to the Company, or any Parent, Subsidiary or Affiliate;

  

	 	(2)	 the date on which the Optionee delivers notice to his or her Employer that the Optionee is terminating the employment relationship (regardless of
whether the notice or termination is lawful or unlawful or is in breach of any contract of employment) unless the Optionee is transferring employment to the Company, or any Parent, Subsidiary or Affiliate; 

 

	 	(3)	 the date on which the Optionee ceases to provide services to the Company, or any Parent, Subsidiary or Affiliate, as appropriate, except where the
Optionee is on an authorized leave of absence; or 

  

	 	(4)	 the date on which the Optionee ceases to be considered an “employee” under Applicable Laws. 

The committee of the Board of Directors of the Company administering the Plan (the “Committee”) shall have
discretion to determine whether Optionee has ceased to be employed by the Company or any Parent, Subsidiary or Affiliate, as appropriate, and the effective date on which such employment terminated. 

In addition, subject to Applicable Law, the Committee in its sole discretion may suspend vesting of the Option if the
Optionee takes a leave of absence from employment with the Company or its Parent, Subsidiary or Affiliate. 
  

	 	b)	 If Optionee ceases to be employed by the Company or any Parent, Subsidiary or Affiliate of the Company, as appropriate, for any reason except death
or disability, this Option may be exercised to the extent (and only to the extent) that it would have been exercisable upon the date of termination of Optionee’s employment, within three (3) months after the date of termination, subject to
Section 2 above, but in any event no later than the Expiration Date of the Option. The date of termination of Optionee’s employment for purposes of this Agreement and the right to exercise this Option shall not be extended by any notice
period mandated under local law. If employment ceases because of death or disability, this Option may be exercised to the extent (and only to the extent) specified in the Plan, subject to Section 2 above. 

 

	4.	 Manner of Exercise; Consideration.    The Option may be exercised by delivery to the Company of the stock option exercise
agreements in the form then approved by the Committee, stating the number of Shares being purchased, the restrictions imposed on the Shares, if any, and such representations and agreements, as may be required by the Company to comply with applicable
laws, together with payment in a form allowed under the Plan. The current forms of stock option exercise form and stock option exercise notice and agreement (the “Exercise Agreement”) are available upon request by emailing
stock_us@oracle.com. 

 Due to administrative restrictions, paying the Exercise Price
by means of the surrender of Shares having a Fair Market Value equal to the applicable Exercise Price of the Option is not an available method of exercise under this Agreement. 

  
 2 

	5.	 Compliance with Laws and Regulations.    The issuance and transfer of Shares shall be subject to compliance by the
Company and Optionee with all applicable requirements of federal, state, local or foreign securities laws and with all applicable requirements of any stock exchange or national market system on which the Common Stock may be listed at the time of
such issuance or transfer. 

  

	6.	 Transferability of Option.    This Option may not be transferred in any manner other than (i) by will, or
(ii) by the laws of descent and distribution, provided however, a U.S. Optionee may transfer a vested portion of the Option for no consideration to or for the benefit of one or more members of the Optionee’s Immediate Family (including,
without limitation, to a trust for the benefit of the Optionee’s Immediate Family) (a “Transferee”), subject to such limits as the Committee may establish, and such Transferee shall remain subject to all the terms and conditions
applicable to the Option prior to such transfer. The Optionee will continue to be treated as the holder of the Option for purposes of the Company’s record keeping and for other purposes deemed appropriate by the Company, including the right to
consent to amendments to this Agreement, notwithstanding that the economic benefits and dispositive control has been transferred to the Transferee. Optionee agrees, on behalf of each Transferee, to exercise the Option upon the direction and
arrangement of payment by such Transferee and further agrees to forward all information provided by the Company (including but not limited to those required under the U.S. securities laws) with respect to the Option to the Transferee. In the
discretion of the Committee, the foregoing right to transfer shall apply to the right to transfer ancillary rights associated with the Option. The term “Immediate Family” shall mean the Optionee’s spouse, qualified same-sex domestic
partner, parents, children, stepchildren, adoptive relationships, sisters, brothers and grandchildren (and, for this purpose, shall also include the Optionee). Optionee acknowledges that the Optionee will continue to be liable for any Tax-Related
Items (as defined in Section 8 below). 

  

	7.	 Tax Consequences.    The general U.S. federal income tax consequences of the grant and exercise and transfer of the
Option, as well as upon disposition of the Shares following exercise, are set forth in the Plan prospectus made available at the Company’s web site at: 

http://my.oracle.com/site/hr/RegionalSites/U.S./usbenefits/stock/index.html 

If Optionee is subject to tax in any other country besides the U.S., the tax treatment in the other country may differ
from that reflected in the Plan prospectus. 
  

	8.	 Tax Withholding Responsibility.    Regardless of any action the Company or the Employer take with respect to any or all
income tax (including federal, state, local and foreign tax), social insurance, payroll tax, payment on account or other tax-related items related to Optionee’s participation in the Plan and legally applicable to Optionee (“Tax-Related
Items”), Optionee acknowledges that the ultimate liability for all Tax-Related Items is and remains Optionee’s responsibility and may exceed the amount actually withheld by the Company and/or the Employer. Optionee further acknowledges
that the Company and/or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the
Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or
eliminate Optionee’s liability for Tax-Related Items or to achieve any particular tax result. Further, if Optionee has become subject to tax in more than one jurisdiction between the date of grant and the date of any relevant taxable event,
Optionee acknowledges that the Company 

  
 3 

 and/or the Employer (or former employer, as applicable) may be required to
withhold or account for Tax-Related Items in more than one jurisdiction. 
 Prior to any relevant taxable or tax
withholding event, as applicable, Optionee shall pay or make adequate arrangements satisfactory to the Company and/or the Employer to satisfy all Tax-Related Items. In this regard, if Optionee is not subject to Section 16 of the Exchange Act,
Optionee authorizes the Company and/or the Employer, or their respective agents, at their discretion to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (1) withholding from Optionee’s
wages or other cash compensation paid to the Optionee by the Company and/or the Employer; (2) withholding from proceeds of the sale of Shares acquired upon exercise of the Option, either through a voluntary sale or through a mandatory sale
arranged by the Company (on Optionee’s behalf pursuant to this authorization); or (3) withholding in Shares subject to the exercised Option. If Optionee is subject to Section 16 of the Exchange Act, Optionee may satisfy the
obligations with regard to all Tax-Related Items by one or a combination of the following: (1) electing to have the Company or Employer withhold from Optionee’s wages or other cash compensation paid to the Optionee by the Company and/or
the Employer; (2) electing to have the Company withhold from proceeds of the sale of Shares acquired upon exercise of the Option, either through a voluntary sale or through a mandatory sale arranged by the Company (on Optionee’s behalf
pursuant to this authorization); or (3) electing to have the Company withhold Shares subject to the exercised Option. 
 To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If
the obligation for the Tax-Related Items is satisfied by withholding in Shares, for tax purposes, Optionee is deemed to have been issued the full number of Shares subject to the exercised Option, notwithstanding that a number of the Shares are held
back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of Optionee’s participation in the Plan. 
 Finally, Optionee shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of Optionee’s
participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to honor the exercise and refuse to deliver the Shares or the proceeds from the sale of Shares if Optionee fails to comply with his or her
obligations in connection with the Tax-Related Items as described in this section. 
  

	9.	 Nature of the Grant.    By entering into this Agreement and accepting the grant of an Option evidenced hereby, Optionee
acknowledges that: (i) the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time unless otherwise provided in the Plan and this
Agreement; (ii) the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted repeatedly in the
past; (iii) all decisions with respect to future grants, if any, will be at the sole discretion of the Company; (iv) Optionee’s participation in the Plan shall not create a right to further employment with the Employer and shall not
interfere with the ability of the Employer to terminate Optionee’s employment relationship at any time; (v) Optionee’s participation in the Plan is voluntary; (vi) the Option and the Shares subject to the Option are extraordinary
items that do not constitute compensation of any kind for services of any kind rendered to the Company or the Employer, and which are outside the scope of Optionee’s employment contract, if any; (vii) the Option

  
 4 

 is not part of normal or expected compensation or salary for any purpose
including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or welfare or retirement benefits (including the 401(k) Savings and Investment
Plan and the Deferred Compensation Plan) or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, the Employer or any Subsidiary or Affiliate of the Company;
(viii) the Options and the Shares subject to the Option are not intended to replace any pension rights or compensation; (ix) the vesting of any Option ceases upon termination of the employment relationship as described in
Section 6(i)(iv) of the Plan except as may otherwise be explicitly provided in the Plan document; (x) the future value of the underlying Shares is unknown and cannot be predicted with certainty, and if the Optionee exercises the Option and
obtains Shares, the value of those Shares may increase or decrease in value, even below the Exercise Price; (xi) if the underlying Shares do not increase in value, the Option will have no value; (xii) the Option grant and Optionee’s
participation in the Plan shall not be interpreted to form an employment contract or relationship with the Company or any Subsidiary or Affiliate of the Company; and furthermore, the grant of an Option will not be interpreted to form an employment
contract with the Employer or any Subsidiary or Affiliate of the Company; (xiii) in consideration of the Option grant, no claim or entitlement to compensation or damages shall arise from termination of the exercisability of the Option or
diminution in value of the Option or Shares purchased through exercise of the Option resulting from termination of Optionee’s employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of local labor laws)
and Optionee irrevocably releases the Company and the Employer from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting this Agreement,
Optionee shall be deemed irrevocably to have waived his or her entitlement to pursue such claim; (xiv) in the event of termination of Optionee’s employment (whether or not in breach of local labor laws), Optionee shall not have any right
to receive any future options under the Plan upon termination of Optionee’s employment relationship with the Employer as described in Section 3 of this Agreement; and (xv) the Option and the benefits under the Plan, if any, will not
necessarily transfer to another company in the case of a merger, take-over or transfers of assets. 
  

	10.	 No Advice Regarding Grant.    The Company is not providing any tax, legal or financial advice, nor is the Company making
any recommendations regarding Optionee’s participation in the Plan, or Optionee’s acquisition or sale of the underlying Shares. Optionee is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding
his or her participation in the Plan before taking any action related to the Plan. 

  

	11.	 Data Privacy Consent.    As a condition of the grant of the Option, the Optionee hereby explicitly and
unambiguously consents to the collection, use, processing and transfer, in electronic or other form, of personal data as described in this paragraph by and among, as applicable, the Employer and the Company and any of its Subsidiaries and Affiliates
for the exclusive purpose of implementing, administering and managing Optionee’s participation in the Plan. 

 The Optionee understands that the Company and any Parent, Subsidiary or Affiliate hold certain personal information about the Optionee, including the Optionee’s name, home address and telephone
number, date of birth, social security number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all options or any other entitlement to Shares awarded, canceled, exercised,
vested, unvested or outstanding in the Optionee’s favor, for the purpose of managing and 

  
 5 

 administering the Plan (“Data”). 

The Optionee acknowledges that Data will be transferred to Fidelity or such other stock plan service providers or
brokers as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan, provided that the Company ensures that the recipient maintains a level of privacy broadly
equivalent to the standard set forth in the Company’s Internal Privacy Policy. The Optionee accepts that these recipients may be located in the United States or the European Economic Area and that the recipient’s country may have different
data privacy laws and protections than Optionee’s country. The Optionee authorizes the Company, its broker and any possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the
Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Optionee’s participation in the Plan, including any requisite transfer of Data to a
designated broker or other third party with whom the Optionee may elect to deposit any Shares acquired upon exercise of the Option, as such Data may be required for the administration of the Plan and/or the subsequent holding of Shares on
Optionee’s behalf. 
 Additional details regarding data privacy are included in the Notice of
Stock Option Grant and in Oracle’s Internal Privacy Policy at: http://my.oracle.com/content/groups/public/@empl/@legal/documents/webcontent/cnt337893.pdf 

 

	12.	 Entire Agreement; Interpretation.    The Plan made available at the Company’s web site at
http://my.oracle.com/site/hr/RegionalSites/U.S./usbenefits/stock/index.html is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements
with respect to the subject matter hereof. The Committee may amend this Agreement and the Plan from time to time. Optionee understands and agrees that the terms of the Option can only be amended in writing. Optionee agrees that the terms of the Plan
govern the Option and that all interpretations and determinations made by the Company (or its Board of Directors and any committee of the Board administering the Plan) with respect to the Plan and this Agreement shall be final and binding on all
persons. This Agreement is governed by Delaware law except for that body of law pertaining to conflict of laws. Unless Optionee is subject to a mutual agreement to arbitrate with the Company, Optionee agrees to institute any legal action or legal
proceeding relating to the Agreement or the Plan in state court in San Mateo County, California or in federal court in San Francisco, California, United States of America. Optionee agrees to submit to the jurisdiction of and agrees that venue is
proper in the aforesaid courts in any such action or proceeding. 

  

	13.	 Electronic Delivery.    The Company may, in its sole discretion, decide to deliver any documents related to current or
future participation in the Plan by electronic means or to request Optionee’s consent to participate in the Plan by electronic means. Optionee hereby consents to receive such documents by electronic delivery and, if requested, to agree to
participate in the Plan through an on-line or electronic system established and maintained by the Company or any third party designated by the Company. 

 

	14.	 Severability.    The provisions of this Agreement are severable and if any one or more provisions are determined
to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable. 

  
 6 

	15.	 409A Disclaimer.    This Agreement shall be interpreted in accordance with, and incorporate the terms and conditions
required by, Section 409A of the U.S. Internal Revenue Code (the “Code”). The Company reserves the right, to the extent the Company deems necessary or advisable in its sole discretion, to unilaterally amend or modify this Agreement or
adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Company determines are necessary or appropriate to ensure that this Option qualifies for exemption from,
or complies with the requirements of, Code Section 409A; provided, however, that the Company makes no representation that the Option will be exempt from, or will comply with, Section 409A of the Code, and makes no undertakings to preclude
Section 409A of the Code from applying to the Option or to ensure that it complies with Section 409A of the Code. For the avoidance of doubt, Optionee hereby acknowledges and agrees, that the Company will have no liability to Optionee or
any other party if the grant, vesting, exercise, issuance of shares or any other transaction under this Agreement is not exempt from, or compliant with, Code Section 409A, or for any action taken by the Company with respect thereto.

  

	16.	 Country-Specific Terms/Notifications.    If Optionee relocates to one of the countries included in Exhibit A to the non
U.S. option agreement, the special terms for such country will apply to him or her, to the extent the Company determines that the application of such terms is necessary or advisable in order to comply with local law or facilitate the administration
of the Plan. As a result, Optionee should review the specific terms/notifications that apply to him or her in his or her particular country to which he/she transfers. These country specific alerts/notifications are available at the Company’s
web site at: http://my.oracle.com/site/hr/RegionalSites/U.S./usbenefits/option/option 

  

	17.	 Additional Terms.    The Company reserves the right to impose other requirements on Optionee’s participation in the
Plan, to the extent the Company determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require Optionee to sign any additional agreements or undertakings that may be necessary
to accomplish the foregoing. 

 By clicking on the “Accept” button, Optionee accepts the Option and
agrees to be bound by its terms as set forth in the Plan and this Agreement. 
 These terms apply to grants made
on or after June 29, 2011. 

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]